Bristol Myers Squibb and Incyte both announced significant artificial intelligence collaborations this week, signaling an accelerating shift in how the industry is deploying AI.

The deals reflect a growing industry trend for companies using AI, aiming to move beyond productivity tools toward deeply integrated systems capable of operating autonomously across core scientific and business functions.

Bristol Myers Squibb deploys Claude enterprise-wide in AI partnership

Bristol Myers Squibb (BMS) entered a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions, giving more than 30,000 employees access to advanced reasoning and agentic AI capabilities.¹ The collaboration builds on over three years of AI investment at BMS and represents a deliberate step beyond conversational AI tools toward agents embedded directly in the workflows that advance drug development.

According to BMS, the company is focusing the deployment on three priority areas. In engineering, teams will use Claude Code to accelerate software and AI development and standardize how capabilities are built across the enterprise. In core drug development workflows, Claude will be evaluated as an agentic layer across research, clinical trial documentation, manufacturing quality processes, and commercial operations, with potential applications ranging from synthesizing decades of proprietary scientific data to drafting clinical study reports and supporting regulatory submissions to identifying root causes of manufacturing deviations in real time.¹ The third priority is connecting Claude to the institutional knowledge distributed across BMS's systems, with full enterprise governance and audit controls.

"Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it," said Greg Meyers, EVP and chief digital and technology officer at BMS. "Anthropic's Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them."

Eric Kauderer-Abrams, head of life sciences at Anthropic, said: "By giving employees access to Claude's agentic capabilities, connected to thousands of data sources across the company, BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time. In a regulated global enterprise, that means medicines reach patients faster, with BMS' scientific depth and operational rigor accelerated by Claude agents at every step."

Incyte expands Genesis Molecular AI collaboration

Incyte expanded its strategic collaboration with Genesis Molecular AI in a deal providing $120 million in upfront consideration, an $80 million cash payment, and a $40 million equity investment. The deal also inlcudes recurring research funding and milestone payments that could exceed $1 billion across five initial collaboration targets.² Additional payments worth several billion dollars could also be earned depending on the number of additional targets nominated over time.

The expanded agreement broadens deployment of Genesis's GEMS platform, which includes leading foundation models for protein-ligand structure and property prediction, across a wider range of challenging targets in Incyte's portfolio. Incyte will also share proprietary experimental data with Genesis to enhance the platform's capabilities. The companies described the arrangement as among the first major pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data.²

"By combining our deep expertise in drug discovery and development and our significant experimental data with Genesis' AI capabilities, we aim to more efficiently advance priority programs against high-value targets and ultimately bring important new medicines to patients," said Pablo J. Cagnoni, M.D., president of Incyte and global head of R&D.

Incyte will have exclusive rights to develop and commercialize any products arising from the collaboration, while Genesis will remain eligible for milestone payments upwards of $232 million per program and royalties on approved product sales.²

Sources

1. Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations Bristol Myers Squibb May 20, 2026 https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Strategic-Agreement-with-Anthropic-to-Position-Claude-Enterprise-as-the-Shared-Intelligence-Platform-Across-Its-Global-Operations/default.aspx
2. Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery Incyte May 20, 2026 https://investor.incyte.com/news-releases/news-release-details/incyte-and-genesis-expand-molecular-ai-collaboration-accelerate